Remove Containment Remove Development Remove Drug Delivery Remove RNA
article thumbnail

Vevye: A New Cyclosporine Solution for Dry Eye Disease

XTalks

Sheppard, MD, MMSc, FACS, professor of ophthalmology at Eastern Virginia Medical School, and mid-atlantic medical director for Eye Care Partners and investigator in the development program. Attendees will understand best practices for novel drug delivery design and development. What Is Dry Eye Disease?

article thumbnail

Introduction To Exosome Therapeutics

Roots Analysis

Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. In addition, they are involved in regulating the expression of the targets that are linked to RNA as they can affect the expression of RNA.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

XPhyto Announces RT-PCR Test for Point-of-Care COVID-19 Detection

The Pharma Data

“Applying 3a’s proprietary enhanced RNA technology to PCR testing was a logical next step in our product development pipeline,” said Dr. . “We are currently developing two saliva-based tests to detect SARS-CoV-2 RNA. . VANCOUVER, BC / ACCESSWIRE / October 28, 2020 / XPhyto Therapeutics Corp.

RNA 52
article thumbnail

Five key drug discovery deals of summer 2023

Drug Discovery World

Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270 which contains a novel selective glucocorticoid receptor agonist formulated in a cutting-edge drug delivery system that overcomes the issues of poor compliance and inefficient delivery of conventional eye drops.”

Drugs 52
article thumbnail

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. These peptides typically contain up to 30 amino acids and can be cationic, amphipathic or both. How are cell-penetrating peptides used?

article thumbnail

mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

Roots Analysis

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases.

article thumbnail

mRNA Synthesis: ManufacturingProcess of Modern Revolutionary Molecule

Roots Analysis

Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. Additionally, they also require appropriate drug delivery systems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases).